- Conditions
- Pharmacogenetic Testing
- Interventions
- Panel-based pharmacogenetic genotyping
- Diagnostic Test
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
- Interventions
- capecitabine, irinotecan hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 115
- States / cities
- Hartford, Connecticut • Boise, Idaho • Cedar Rapids, Iowa + 76 more
- Conditions
- Pharmacogenomic Drug Interaction
- Interventions
- Panel-based pharmacogenetic genotyping
- Diagnostic Test
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Jacksonville, Florida
- Conditions
- Mood Disorders, Anxiety Disorders, Psychotic Disorders
- Interventions
- Personalised medication advice based on pharmacogenetic testing
- Other
- Lead sponsor
- Parnassia Groep
- Other
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Thromboembolism
- Interventions
- IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
- Genetic · Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation, Breast Cancer
- Interventions
- Availability of clinical decision support based on pharmacogenomic results.
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Use of Prescription Medications, Pharmacogenetic Testing
- Interventions
- Panel-based pharmacogenetic genotyping
- Diagnostic Test
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Tobacco Smoking
- Interventions
- Genetic Education Session, Nutrition Education Session
- Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Acute Coronary Syndrome, Cardiovascular Diseases
- Interventions
- CYP2C19 genotyping
- Genetic
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer
- Interventions
- DPYD or UGT1A1 variants
- Genetic
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Venous Thromboembolism, Bleeding
- Interventions
- Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing
- Genetic · Other
- Lead sponsor
- Gwen McMillin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Acute Pain, Post Operative Pain
- Interventions
- Pharmacogenetic testing, Pharmacist note with genotype-guided analgesic recommendations, Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania